Psychiatr. praxi 2019; 20(3): 142-148

Účinná úprava terapie deprese ve světle současných poznatků

Na XVIII. celostátní konferenci biologické psychiatrie v Luhačovicích proběhlo 13. června 2019 sympozium věnované změnám
medikace v léčbě depresivní poruchy. Přineslo odpovědi na otázky, kdy po nasazení antidepresiva změnit nebo augmentovat
léčbu, jakým způsobem změnu terapie provést, jaká antidepresiva mají nejlepší poměr mezi účinností a rizikem vysazení
léčby a u jakých pacientů je vhodný agomelatin včetně praktických aspektů převedení z předchozí léčby, zvýšení dávky a
možností kombinací. Přinášíme souhrn informací, které v rámci sympozia zazněly.

Published: October 11, 2019  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Účinná úprava terapie deprese ve světle současných poznatků. Psychiatr. praxi. 2019;20(3):142-148.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Cipriani A, Furukawa TA, Salanti G, et al. Comparative efficacy and acceptability of 21 antidepressant drugs for the acute treatment of adults with major depressive disorder: a systematic review and network meta-analysis. Lancet. 2018 Apr 7; 391(10128): 1357-1366. Go to original source... Go to PubMed...
    2. Kennedy SH, Lam RW, McIntyre RS, et al; CANMAT Depression Work Group. Canadian Network for Mood and Anxiety Treatments (CANMAT) 2016 Clinical Guidelines for the Management of Adults with Major Depressive Disorder: Section 3. Pharmacological Treatments. Can J Psychiatry. 2016 Sep; 61(9): 540-560. Go to original source... Go to PubMed...
    3. Laux G, Huttner NA; VIVALDI study group. Subgroup analysis of the non-interventional study VIVALDI: agomelatine in treatment-na?ve patients, in combination therapy and after treatment switch. Int J Psychiatry Clin Pract. 2014 Jun; 18(2): 86-96. Go to original source... Go to PubMed...
    4. Stein DJ, Picarel-Blanchot F, Kennedy SH. Efficacy of the novel antidepressant agomelatine for anxiety symptoms in major depression. Hum Psychopharmacol. 2013 Mar; 28(2): 151-159. Go to original source... Go to PubMed...
    5. Gargoloff PD, Corral R, Herbst L, et al. Effectiveness of agomelatine on anhedonia in depressed patients: an outpatient, open-label, real-world study. Hum Psychopharmacol. 2016 Nov; 31(6): 412-418. Go to original source... Go to PubMed...
    6. Avila A, Cardona X, Martin-Baranera M, et al. Agomelatine for Depression in Parkinson Disease: Additional Effect on Sleep and Motor Dysfunction. J Clin Psychopharmacol. 2015 Dec;3 5(6): 719-723. Go to original source... Go to PubMed...
    7. Laursen TM, Musliner KL, Benros ME, et al. Mortality and life expectancy in persons with severe unipolar depression. J Affect Disord. 2016 Mar 15; 193: 203-207. Go to original source... Go to PubMed...
    8. Ramasubbu R, Taylor VH, Samaan Z, et al; Canadian Network for Mood and Anxiety Treatments (CANMAT) Task Force. The Canadian Network for Mood and Anxiety Treatments (CANMAT) task force recommendations for the management of patients with mood disorders and select comorbid medical conditions. Ann Clin Psychiatry. 2012 Feb; 24(1): 91-109. Go to PubMed...
    9. Jia P, Liu C, Wu N, et al. Agomelatine protects against myocardial ischemia reperfusion injury by inhibiting mitochondrial permeability transition pore opening. Am J Transl Res. 2018 May 15; 10(5): 1310-1323.
    10. Billioti de Gage S, Collin C, Le-Tri T, et al. Antidepressants and Hepatotoxicity: A Cohort Study among 5 Million Individuals Registered in the French National Health Insurance Database. CNS Drugs. 2018 Jul; 32(7): 673-684. Go to original source... Go to PubMed...
    11. ##
    12. Rush AJ, Trivedi MH, Wisniewski SR, et al. Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report. Am J Psychiatry. 2006 Nov; 163(11): 1905-1917. Go to original source... Go to PubMed...
    13. Malhi GS, Outhred T, Hamilton A, et al. Royal Australian and New Zealand College of Psychiatrists clinical practice guidelines for mood disorders: major depression summary. Med J Aust. 2018 Mar 5; 208(4): 175-180. Go to original source... Go to PubMed...
    14. Lejoyeux M, Matharan S, de Bodinat C. How to switch to agomelatine after an unsuccessful try with paroxetine or venlafaxine. CNS Spectr. 2015 Feb; 20(1): 29-38. Go to original source... Go to PubMed...
    15. Bhat V, Kennedy SH. Recognition and management of antidepressant discontinuation syndrome. J Psychiatry Neurosci. 2017 Jun; 42(4): E7-E8. Go to original source... Go to PubMed...
    16. Davies J, Read J. A systematic review into the incidence, severity and duration of antidepressant withdrawal effects: Are guidelines evidence-based? Addict Behav. 2019 Oct; 97: 111-121. Go to original source... Go to PubMed...
    17. Henssler J, Bschor T, Baethge C. Combining Antidepressants in Acute Treatment of Depression: A Meta-Analysis of 38 Studies Including 4511 Patients. Can J Psychiatry. 2016 Jan; 61(1): 29-43. Go to original source... Go to PubMed...
    18. Zuilhof Z, Norris S, Blondeau C, et al. Optimized regimens of combined medications for the treatment of major depressive disorder: a double-blind, randomized-controlled trial. Neuropsychiatr Dis Treat. 2018 Nov 22;14:3209-3218. Go to original source...
    19. Laux G, Huttner NA; VIVALDI study group. Subgroup analysis of the non-interventional study VIVALDI: agomelatine in treatment-na?ve patients, in combination therapy and after treatment switch. Int J Psychiatry Clin Pract. 2014 Jun; 18(2): 86-96. Go to original source... Go to PubMed...
    20. Medvedev VE. [Valdoxan (agomelatine) in combined therapy of moderate and severe non-psychotic depressions]. Zh Nevrol Psikhiatr Im S S Korsakova. 2012; 112(5): 37-40.
    21. Zajecka J, Schatzberg A, Stahl S, et al. Efficacy and safety of agomelatine in the treatment of major depressive disorder: a multicenter, randomized, double-blind, placebo-controlled trial. J Clin Psychopharmacol. 2010 Apr; 30(2): 135-144. Go to original source... Go to PubMed...
    22. Kennedy SH, Emsley R. Placebo-controlled trial of agomelatine in the treatment of major depressive disorder. Eur Neuropsychopharmacol. 2006 Feb; 16(2): 93-100. Go to original source... Go to PubMed...
    23. Rink L, Braun C, Bschor T, et al. Dose Increase Versus Unchanged Continuation of Antidepressants After Initial Antidepressant Treatment Failure in Patients With Major Depressive Disorder: A Systematic Review and Meta-Analysis of Randomized, Double-Blind Trials. J Clin Psychiatry. 2018 May/Jun; 79(3). Go to original source...

    Return to the content


    Psychiatry for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.